SCHEMBL5761672

SCHEMBL5761672

Cc1ccccc1CNS(=O)(=O)c1ccc(Cc2ccc3oc(=O)cc(C(F)(F)F)c3c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 4/20 0.44
HPGD P15428 3/20 0.43
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP1A2 P05177 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TLR9 Q9NR96 1/20 0.40
NAMPT P43490 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
GLA P06280 2/20 0.37
PKM P14618 2/20 0.37
AR P10275 3/20 0.37
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762510 0.92 NAMPT (0.44) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5759934 0.89 ALDH1A1 (0.41) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5860248 0.89 AR (0.46) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5861395 0.88 GAA (0.38) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5860408 0.88 GAA (0.46) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5760027 0.87 ALDH1A1 (0.37) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5861368 0.87 LMNA (0.45) MEN1KMT2AGAAALDH1A1LMNA
SCHEMBL5762259 0.87 ALDH1A1 (0.49) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5762075 0.86 AR (0.40) MEN1KMT2AGAAHPGDKDM4E
SCHEMBL5761950 0.85 AR (0.48) MEN1KMT2AGAAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT MEN1 1982/4885KMT2A 816/4885GAA 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.